As Gilead (GILD +0.6%) awaits FDA approval of its Quad on August 27, Deutsche says U.S. HIV...


As Gilead (GILD +0.6%) awaits FDA approval of its Quad on August 27, Deutsche says U.S. HIV treatment guidelines are already adding the drug. The firm thinks consensus expectations are undervaluing its potential, and its launch will surprise to the upside. The firm raises its price target to $68 from $65 and reiterates its Buy rating on the stock.

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs